CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Accelerate Diagnostics, Inc. - AXDX CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Accelerate Diagnostics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 4.50-19.50
Average Volume (10 days) 8,230.00
Average Volume (3 months) 567.05K
Market Cap 97.13M
P/E Ratio -100.00K
Shares Outstanding 9.98M
Revenue 11.67M
EPS -34.77
Dividend (Yield %) N/A
Beta 1.18
Next Earnings Date Nov 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

Accelerate Diagnostics, Inc. Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Accelerate Diagnostics Inc Earnings Release
Q3 2023 Accelerate Diagnostics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 12.752 11.782 11.165 9.297 5.67
Revenue 12.752 11.782 11.165 9.297 5.67
Total Operating Expense 71.992 73.549 74.865 82.128 86.039
Selling/General/Admin. Expenses, Total 39.193 49.236 46.904 51.886 54.014
Research & Development 26.915 21.943 21.255 25.345 26.838
Depreciation / Amortization 2
Operating Income -59.24 -61.767 -63.7 -72.831 -80.369
Interest Income (Expense), Net Non-Operating -3.103 -15.87 -14.443 -11.571 -7.718
Net Income Before Taxes -62.57 -77.657 -78.203 -84.416 -88.115
Net Income After Taxes -62.493 -77.702 -78.208 -84.305 -88.326
Net Income Before Extra. Items -62.493 -77.702 -78.208 -84.305 -88.326
Net Income -62.493 -77.702 -78.208 -84.305 -88.326
Income Available to Common Excl. Extra. Items -62.493 -77.702 -78.208 -84.305 -88.326
Income Available to Common Incl. Extra. Items -62.493 -77.702 -78.208 -84.305 -88.326
Diluted Net Income -62.493 -77.702 -78.208 -84.305 -88.326
Diluted Weighted Average Shares 8.2161 6.1727 5.601 5.4506 5.4494
Diluted EPS Excluding Extraordinary Items -7.60616 -12.588 -13.9632 -15.4671 -16.2084
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -7.8882 -13.1454 -13.9632 -15.4671 -16.2084
Cost of Revenue, Total 9.449 7.663 6.706 4.897 3.187
Gross Profit 3.303 4.119 4.459 4.4 2.483
Other, Net -0.227 -0.02 -0.06 -0.014 -0.028
Unusual Expense (Income) -3.565 -5.293
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 2.921 2.812 2.972 2.96 3.861
Revenue 2.921 2.812 2.972 2.96 3.861
Cost of Revenue, Total 2.122 1.801 2.131 2.381 2.781
Gross Profit 0.799 1.011 0.841 0.579 1.08
Total Operating Expense 28.811 18.874 16.932 17.921 21.651
Selling/General/Admin. Expenses, Total 7.564 10.105 8.771 8.255 11.493
Research & Development 5.82 6.968 6.03 7.285 7.576
Operating Income -25.89 -16.062 -13.96 -14.961 -17.79
Interest Income (Expense), Net Non-Operating -6.729 -0.778 -0.705 -0.886 -0.626
Other, Net 0.04 0.045 -0.021 -0.049 -0.107
Net Income Before Taxes -32.579 -16.795 -14.686 -15.896 -18.523
Net Income After Taxes -32.735 -16.795 -14.609 -15.896 -18.523
Net Income Before Extra. Items -32.735 -16.795 -14.609 -15.896 -18.523
Net Income -32.735 -16.795 -14.609 -15.896 -18.523
Income Available to Common Excl. Extra. Items -32.735 -16.795 -14.609 -15.896 -18.523
Income Available to Common Incl. Extra. Items -32.735 -16.795 -14.609 -15.896 -18.523
Diluted Net Income -32.735 -16.795 -14.609 -15.896 -18.523
Diluted Weighted Average Shares 1.1009 9.8301 9.7497 8.7011 7.6231
Diluted EPS Excluding Extraordinary Items -29.7348 -1.70853 -1.49841 -1.8269 -2.42985
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -21.8791 -1.70853 -1.49841 -1.8269 -2.45596
Unusual Expense (Income) 13.305 0 0 0 -0.199
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 56.014 73.331 81.987 121.852 177.64
Cash and Short Term Investments 45.561 63.618 68.269 108.451 166.478
Cash & Equivalents 34.905 39.898 35.781 61.014 66.26
Short Term Investments 10.656 23.72 32.488 47.437 100.218
Total Receivables, Net 2.416 2.32 1.55 3.222 1.86
Accounts Receivable - Trade, Net 2.416 2.32 1.55 3.222 1.86
Prepaid Expenses 0.818 0.768 1.172 0.955 0.98
Other Current Assets, Total 2.025 1.558 1.78 1.165 0.576
Total Assets 65.015 83.047 93.425 134.424 185.265
Property/Plant/Equipment, Total - Net 7.759 7.899 9.318 11.822 7.303
Property/Plant/Equipment, Total - Gross 18.58 18.698 20.153 21.687 16.014
Accumulated Depreciation, Total -10.821 -10.799 -10.835 -9.865 -8.711
Intangibles, Net 0.114
Total Current Liabilities 66.557 6.945 6.969 8.162 7.763
Accounts Payable 4.501 1.983 1.29 2.351 1.322
Accrued Expenses 3.983 4.431 4.75 5.54 6.224
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 57.526 0.08 0.553
Other Current Liabilities, Total 0.547 0.451 0.376 0.271 0.217
Total Liabilities 87.279 118.118 156.237 141.803 127.89
Total Long Term Debt 17.64 107.984 145.87 130.043 120.074
Capital Lease Obligations 0.782
Other Liabilities, Total 3.082 3.189 3.398 3.598 0.053
Total Equity -22.264 -35.071 -62.812 -7.379 57.375
Preferred Stock - Non Redeemable, Net 0.004 0.004 0 0 0
Common Stock 0.097 0.068 0.058 0.055 0.054
Additional Paid-In Capital 630.341 580.652 475.072 452.344 432.885
Retained Earnings (Accumulated Deficit) -607.239 -570.668 -492.966 -414.653 -330.348
Other Equity, Total -0.4 -0.06 0.091 -0.058 -0.149
Total Liabilities & Shareholders’ Equity 65.015 83.047 93.425 134.424 185.265
Total Common Shares Outstanding 97.4775 67.649 57.6079 54.7088 54.2319
Total Inventory 5.194 5.067 9.216 8.059 7.746
Other Long Term Assets, Total 1.242 1.817 2.12 0.75 0.208
Long Term Debt 16.858 107.984 145.87 130.043 120.074
Treasury Stock - Common -45.067 -45.067 -45.067 -45.067 -45.067
Total Preferred Shares Outstanding 3.95455 3.95455
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 42.834 56.014 66.272 48.059 61.111
Cash and Short Term Investments 31.865 45.561 55.394 36.772 50.376
Cash & Equivalents 29.408 34.905 38.987 4.581 13.654
Short Term Investments 2.457 10.656 16.407 32.191 36.722
Total Receivables, Net 2.427 2.416 2.393 2.935 2.114
Accounts Receivable - Trade, Net 2.427 2.416 2.393 2.935 2.114
Total Inventory 5.27 5.194 5.392 5.304 5.505
Prepaid Expenses 1.697 0.818 1.119 1.429 1.522
Other Current Assets, Total 1.575 2.025 1.974 1.619 1.594
Total Assets 51.002 65.015 75.847 58.726 70.357
Property/Plant/Equipment, Total - Net 7.073 7.759 7.952 8.816 7.455
Property/Plant/Equipment, Total - Gross 18.208 18.58 18.772 19.816 18.338
Accumulated Depreciation, Total -11.135 -10.821 -10.82 -11 -10.883
Other Long Term Assets, Total 1.095 1.242 1.623 1.851 1.791
Total Current Liabilities 68.125 66.557 66.084 66.929 113.875
Accounts Payable 3.524 4.501 2.819 2.221 2.717
Accrued Expenses 6.425 3.983 5.383 7.132 4.941
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 57.708 57.526 57.358 57.241 105.819
Other Current Liabilities, Total 0.468 0.547 0.524 0.335 0.398
Total Liabilities 89.727 87.279 85.835 120.69 126.413
Total Long Term Debt 18.135 17.64 16.997 51.007 9.541
Long Term Debt 17.43 16.858 16.299 49.624 9.377
Other Liabilities, Total 3.467 3.082 2.754 2.754 2.997
Total Equity -38.725 -22.264 -9.988 -61.964 -56.056
Preferred Stock - Non Redeemable, Net 0.004 0.004 0.004 0.004 0.004
Common Stock 0.1 0.097 0.097 0.08 0.069
Additional Paid-In Capital 630.903 630.341 627.853 560.185 547.381
Retained Earnings (Accumulated Deficit) -624.034 -607.239 -592.63 -576.734 -558.211
Treasury Stock - Common -45.067 -45.067 -45.067 -45.067 -45.067
Other Equity, Total -0.631 -0.4 -0.245 -0.432 -0.232
Total Liabilities & Shareholders’ Equity 51.002 65.015 75.847 58.726 70.357
Total Common Shares Outstanding 99.6283 97.4775 97.241 79.7014 68.7116
Total Preferred Shares Outstanding 3.95455 3.95455 3.95455 3.95455 3.95455
Capital Lease Obligations 0.705 0.782 0.698 1.383 0.164
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -62.493 -77.702 -78.208 -84.305 -88.326
Cash From Operating Activities -48.728 -47.323 -50.394 -64.794 -67.756
Cash From Operating Activities 3 2.518 2.997 2.602 2.561
Amortization
Non-Cash Items 8.512 27.963 28.162 22.997 21.328
Changes in Working Capital 2.253 -0.102 -3.345 -6.088 -3.319
Cash From Investing Activities 12.417 8.304 13.606 52.811 -20.138
Capital Expenditures -0.554 -0.603 -1.362 -0.33 -0.998
Other Investing Cash Flow Items, Total 12.971 8.907 14.968 53.141 -19.14
Cash From Financing Activities 31.63 43.226 11.633 6.823 125.771
Financing Cash Flow Items -0.192 -1.24 0 0 -4.992
Issuance (Retirement) of Stock, Net 33.103 44.826 6.421 6.823 -40.737
Issuance (Retirement) of Debt, Net -1.281 -0.36 5.212 0 171.5
Foreign Exchange Effects -0.312 -0.09 -0.078 -0.086 -0.13
Net Change in Cash -4.993 4.117 -25.233 -5.246 37.747
Cash Taxes Paid 0 0 0.043 0.041 0.651
Cash Interest Paid 2.214 4.288 4.288 4.288 2.001
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.795 -62.493 -47.884 -31.988 -13.465
Cash From Operating Activities -13.367 -48.728 -39.178 -25.605 -12.606
Cash From Operating Activities 0.802 3 2.207 1.435 0.616
Non-Cash Items 1.27 8.512 5.475 4.078 -0.024
Cash Taxes Paid 0
Cash Interest Paid 0 2.214 2.214 1.506
Changes in Working Capital 1.356 2.253 1.024 0.87 0.267
Cash From Investing Activities 8.209 12.417 6.575 -9.213 -13.641
Capital Expenditures -0.012 -0.554 -0.446 -0.447 -0.447
Other Investing Cash Flow Items, Total 8.221 12.971 7.021 -8.766 -13.194
Cash From Financing Activities -0.077 31.63 31.756 -0.28 0.077
Issuance (Retirement) of Stock, Net 0 33.103 33.063 0.144 0.077
Foreign Exchange Effects -0.262 -0.312 -0.064 -0.219 -0.074
Net Change in Cash -5.497 -4.993 -0.911 -35.317 -26.244
Issuance (Retirement) of Debt, Net -0.077 -1.281 -1.115 -0.424
Financing Cash Flow Items -0.192 -0.192

Accelerate Diagnostics, Inc. Company profile

About Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Accelerate Diagnostics Inc revenues increased 6% to $11.8M. Net loss decreased 1% to $77.7M. Revenues reflect Foreign segment increase of 93% to $1.7M. Lower net loss reflects Sales, general and administrative - Bala decrease of 9% to $31.6M (expense), Other expense (net) decrease of 67% to $20K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.40 to -$1.26.

Equity composition

Common Stock no Par, 01/11, 14M auth., 10,757,317 issd. Insiders own 31.63%. IPO 11/83, 10M shs @ $.10 by T. Geimer Securities. PO 11/96, 1M shs @ $7 by Janco Partners Inc. 11/96, 1-for-4 reverse stock split. FY'99 Q's are reclassified. *10/03, Exchange change from OTC to AMEX. 1/03 Q is restated.

Industry: Advanced Medical Equipment & Technology (NEC)

3950 S Country Club Rd Ste 470 Bldg 3-307
DENVER
COLORADO 80203
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.49 Price
+1.010% 1D Chg, %
Long position overnight fee 0.0353%
Short position overnight fee -0.0572%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

14,760.30 Price
+0.590% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,596.23 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,638.15 Price
0.000% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading